Profile data is unavailable for this security.
About the company
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
- Revenue in USD (TTM)6.15bn
- Net income in USD1.47bn
- Incorporated2012
- Employees10.00k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Mergers & acquisitions
| Acquired company | ZTS:NYQ since announced | Transaction value |
|---|---|---|
| Phoenix Central Laboratory For Veterinarians Inc | -7.59% | -- |
| Platinum Performance Inc | 3.36% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iqvia Holdings Inc | 10.88bn | 236.00m | 28.43bn | 58.00k | 124.99 | 4.64 | 19.52 | 2.61 | 1.17 | 1.21 | 54.05 | 31.60 | 0.4794 | -- | 4.52 | 187,603.50 | 1.21 | 2.15 | 1.44 | 2.66 | 34.37 | 32.04 | 2.52 | 3.61 | -- | 1.99 | 0.6435 | 0.00 | 7.32 | 15.35 | -27.97 | -0.2298 | 39.04 | -- |
| Regeneron Pharmaceuticals Inc | 7.62bn | 2.09bn | 37.23bn | 7.40k | 18.94 | 3.60 | 16.28 | 4.88 | 18.21 | 18.69 | 66.42 | 95.74 | 0.616 | 0.7459 | 3.13 | 1,029,959.00 | 16.88 | 17.74 | 19.37 | 20.75 | 92.21 | 92.91 | 27.40 | 23.68 | 3.51 | 25.23 | 0.0635 | 0.00 | 14.28 | 26.10 | 55.86 | 41.14 | 19.63 | -- |
| Vertex Pharmaceuticals Incorporated | 3.62bn | 583.76m | 53.95bn | 2.50k | 93.46 | 10.27 | 81.97 | 14.90 | 2.24 | 8.25 | 13.92 | 20.42 | 0.5966 | 3.39 | 8.80 | 1,447,865.00 | 9.21 | -5.11 | 11.49 | -6.65 | 86.60 | 88.18 | 15.43 | -8.99 | 3.32 | 402.49 | 0.0992 | -- | 22.46 | 20.25 | 103.80 | -- | 13.20 | -- |
| Zoetis Inc | 6.15bn | 1.47bn | 56.17bn | 10.00k | 38.62 | 20.99 | 29.91 | 9.13 | 3.05 | 3.03 | 12.74 | 5.62 | 0.566 | 1.38 | 6.28 | 615,000.00 | 13.57 | 10.65 | 14.98 | 12.75 | 67.74 | 66.05 | 23.97 | 16.42 | 3.02 | 9.62 | 0.7065 | 23.63 | 9.76 | 5.01 | 28.53 | 22.37 | 12.93 | 20.91 |
| Allergan plc | 15.82bn | -9.27bn | 60.28bn | 16.90k | -- | 1.03 | -- | 3.81 | -27.89 | -27.85 | 47.82 | 178.22 | 0.1574 | 2.40 | 5.42 | 935,952.70 | -9.21 | -3.61 | -10.01 | -3.89 | 84.97 | 83.23 | -58.53 | -28.24 | 0.883 | 0.0042 | 0.278 | -- | -0.9617 | 43.41 | 24.17 | -- | -3.81 | -- |
| Celgene Corporation | 16.98bn | 5.80bn | 78.30bn | 8.85k | 13.72 | 6.48 | 12.13 | 4.61 | 8.02 | 8.13 | 23.50 | 16.99 | 0.4494 | 1.30 | 7.56 | 1,918,437.00 | 15.35 | 10.88 | 17.35 | 12.12 | 96.31 | 95.94 | 34.16 | 24.47 | 2.80 | 6.52 | 0.6208 | 0.00 | 17.52 | 18.67 | -4.89 | 22.52 | 18.86 | -- |
| Gilead Sciences, Inc. | 22.37bn | 2.71bn | 82.32bn | 11.00k | 30.91 | 4.00 | 20.06 | 3.68 | 2.11 | 2.09 | 17.47 | 16.27 | 0.3623 | 5.37 | 6.60 | 2,033,182.00 | 4.36 | 23.08 | 5.20 | 28.22 | 79.60 | 84.37 | 12.04 | 43.52 | 2.87 | 6.07 | 0.5425 | 17.01 | -15.24 | 14.59 | -46.06 | 12.17 | 37.10 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2019 | 36.46m | 7.64% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 22.50m | 4.71% |
| SSgA Funds Management, Inc.as of 30 Sep 2019 | 19.60m | 4.10% |
| State Farm Investment Management Corp.as of 30 Sep 2019 | 19.12m | 4.01% |
| AllianceBernstein LPas of 30 Sep 2019 | 14.12m | 2.96% |
| Fidelity Management & Research Co.as of 30 Sep 2019 | 11.67m | 2.44% |
| Polen Capital Management LLCas of 30 Sep 2019 | 10.53m | 2.21% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2019 | 10.36m | 2.17% |
| ClearBridge Investments LLCas of 30 Sep 2019 | 9.07m | 1.90% |
| Massachusetts Financial Services Co.as of 30 Sep 2019 | 7.56m | 1.58% |
